Table 3.

Correlations of reductions in plasma chemokines and clinical outcome measures after 24 weeks of combination treatment with leflunomide and MTX in RA patients

	Plasma MCP-1	Plasma TARC	Plasma MDC
VAS pain score	0·469 (0·302)	0·286 (0·463)	0·219 (0·581)
Patient global assessment	0·714 (0·088)	−0·183 (0·644)	0·150 (0·708)
Physician global assessment	0·714 (0·088)	−0·200 (0·613)	0·217 (0·581)
Swollen joint score	0·577 (0·200)	0·286 (0·463)	0·614 (0·086)
ESR	0·857 (0·024)*	−0·117 (0·776)	0·283 (0·463)
CRP	0·393 (0·396)	0·833 (0·008)*	−0·233 (0·552)
HAQ score	0·618 (0·139)	0·362 (0·336)	0·293 (0·437)

Results are expressed as the correlation coefficient r (P-value).

^*P-values less than 0·05 are considered significant using Spearman's rank correlation test.